Atripla

Product manufactured by Remedyrepack Inc.

Application Nr Approved Date Route Status External Links
NDA021937 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Atripla ® Is Indicated As A Complete Regimen Or In Combination With Other Antiretroviral Agents For The Treatment Of Hiv-1 Infection In Adults And Pediatric Patients Weighing At Least 40 Kg. Atripla Is A Three-Drug Combination Of Efavirenz (Efv), A Non-Nucleoside Reverse Transcriptase Inhibitor, And Emtricitabine (Ftc) And Tenofovir Disoproxil Fumarate (Tdf), Both Hiv-1 Nucleoside Analog Reverse Transcriptase Inhibitors, And Is Indicated As A Complete Regimen Or In Combination With Other Antiretroviral Agents For The Treatment Of Hiv-1 Infection In Adults And Pediatric Patients Weighing At Least 40 Kg. ( 1 )

All Formulated Excipients (0 Total)

None

Active Ingredients ( 3 Total)

Comments